Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

7.0K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Tumor Progression02:07

Tumor Progression

7.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticancer activity and potential mechanisms of 1C, a ginseng saponin derivative, on prostate cancer cells.

Journal of ginseng research·2018
Same author

Integrating microbial biomass, composition and function to discern the level of anthropogenic activity in a river ecosystem.

Environment international·2018
Same author

c-Jun-mediated microRNA-302d-3p induces RPE dedifferentiation by targeting p21<sup>Waf1/Cip1</sup>.

Cell death & disease·2018
Same author

High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma.

Human pathology·2018
Same author

Comparison of the efficacy of dispensing granules with traditional decoction: a systematic review and meta-analysis.

Annals of translational medicine·2018
Same author

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis.

Journal of digestive diseases·2018

Related Experiment Video

Updated: Mar 6, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.7K

Potential mechanisms underlying CDK5 related Osteosarcoma progression.

Hang-Xing Bao1,2, Qing Bi3,4, Yong Han5,4

  • 1a Department of Orthopedics , the First Clinical Medical College of Zhejiang Chinese Medical University , Hangzhou , PR China.

Expert Opinion on Therapeutic Targets
|March 22, 2017
PubMed
Summary

Cyclin-dependent kinase 5 (CDK5) overexpression in osteosarcoma correlates with poor survival, linked to enhanced energy production and immune evasion. Targeting CDK5 may offer new therapeutic strategies for this bone cancer.

Keywords:
Osteosarcomacyclin-dependent kinase 5therapeutic targetstumor immune escape

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.7K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.6K

Related Experiment Videos

Last Updated: Mar 6, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.7K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.7K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Osteosarcoma requires novel prognostic biomarkers and therapeutic targets.
  • Cyclin-dependent kinase 5 (CDK5) is implicated in various cancers but its role in osteosarcoma is unclear.

Purpose of the Study:

  • To investigate the association between CDK5 expression and osteosarcoma patient prognosis.
  • To explore the molecular mechanisms of CDK5 in osteosarcoma progression.

Main Methods:

  • Analysis of publicly available gene expression datasets.
  • Correlation of CDK5 expression with patient survival data.

Main Results:

  • CDK5 overexpression is linked to poor survival in osteosarcoma patients.
  • Activated tricarboxylic acid (TCA) cycle and repressed antigen presentation characterize high CDK5 expression tumors.
  • Key genes like MELK associated with CDK5-driven osteosarcoma progression were identified.

Conclusions:

  • CDK5 plays a pro-malignant role in osteosarcoma.
  • Enhanced energy production and tumor immune escape are potential therapeutic targets.
  • Further research into CDK5-based treatments for osteosarcoma is recommended.